Bradley Carthon, MD
Medical Oncology · Atlanta, GANPI 1700907276
Payments from drug & device makers
Across 313 payments — averaging $8540.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1.1M
- Alkermes, Inc.$514K
- E.r. Squibb & Sons, L.L.C.$423K
- Medivation LLC.$384K
- AstraZeneca$96K
- Merck$78K
- plus $103K from 8 others
What the payments were for
- Consulting fees$26,57487%
- Speaking & faculty fees$3,60012%
- Travel & lodging$680%
- Food & beverage$3671%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 83 | $1,074,572 |
| Alkermes, Inc. | 41 | $514,333 |
| E.r. Squibb & Sons, L.L.C. | 19 | $423,051 |
| Medivation LLC. | 123 | $384,431 |
| AstraZeneca | 10 | $95,797 |
| Merck | 8 | $77,613 |
| Gilead | 12 | $40,144 |
| Sanofi US Services Inc. | 7 | $22,686 |
| Clovis Oncology, Inc. | 2 | $19,890 |
| Amgen | 1 | $10,656 |
| Immunomedics, Inc. | 3 | $6,881 |
| Eisai Inc. | 2 | $2,625 |
| Genentech, Inc. | 1 | $319 |
| Verity Pharmaceuticals Inc. | 1 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,673,050 in reported general payments places this provider in the 90th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 123 | $1,354,473 |
| OrgovyxRelugolix | 84 | $218,332 |
| NubeqaDarolutamide | 11 | $114,014 |
| Abiraterone Acetate | 127 | $77,396 |
| Prednisone | 103 | $491 |
| Bicalutamide | 11 | $183 |
| Prochlorperazine Maleate | 16 | $154 |
| Oxycodone Hcl | 11 | $86 |
| Amlodipine Besylate | 13 | $54 |
| Dexamethasone | 13 | $53 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Atlanta
- Suresh RamalingamAtlanta$10.5M
- Jonathan KaufmanAtlanta$7.7M
- Nabil SabaAtlanta$2.8M
- Olumide GbolahanAtlanta$2.7M
- Amelia LangstonAtlanta$2.1M
- Ragini KudchadkarAtlanta$2M
- Nisha JosephAtlanta$1.7M
- Patricia RichAtlanta$1.1M
- Eyal MeiriAtlanta$1.1M
- Dong ShinAtlanta$406K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.